Heart failure & cardiomyopathies
Pre-Emptive Treatment of Heart Failure Exacerbations in Patients Managed with the HeartLogic™ Algorithm
Study context
- Population
- Patients with history of heart failure (HF) (LVEF ≤40% or ≥1 episode of clinical HF with NT-proBNP ≥450 ng/L) implanted with an ICD enabling HeartLogic index calculation, 10 French centresplanned enrolment
- Participants
- 310 patients
- Primary endpoint
- Unscheduled hospitalisation for HF
- Follow-up
- 12 months
Methodological detailsstudy protocol, investigator-initiated, multicentre, non-randomised, blind independent event adjudication, Secondary endpoints: all-cause mortality, CV death, HF-related death, unscheduled hospitalisations for ventricular or atrial arrhythmia, HeartLogic index evolution; biobanking, quality of life, safety of HeartLogic-triggered diuretic initiation or increase
- Study protocol
- Investigator-initiated
- Multicentre
- Non-randomised
- Blind independent event adjudication
- Secondary endpoints: all-cause mortality, CV death, HF-related death, unscheduled hospitalisations for ventricular or atrial arrhythmia, HeartLogic index evolution; biobanking, quality of life, safety of HeartLogic-triggered diuretic initiation or increase
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Pre-Emptive Treatment of Heart Failure Exacerbations in Patients Managed with the HeartLogic™ Algorithm. ESC Heart Fail. Published 17 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →